Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Jul 27, 2026; 18(7): 119397
Published online Jul 27, 2026. doi: 10.4240/wjgs.v18.i7.119397
Published online Jul 27, 2026. doi: 10.4240/wjgs.v18.i7.119397
Clinical and radiomic characteristics of transarterial chemoembolization combined with immunotherapy in hepatocellular carcinoma
Qian Xia, Wei Shan, Hao Yan, Department of Interventional Vascular Surgery, General Hospital of Northern Theater Command, Shenyang 110001, Liaoning Province, China
Co-first authors: Qian Xia and Wei Shan.
Author contributions: Xia Q and Shan W designed the research, collected and organized clinical and imaging data, performed statistical analysis, and drafted the initial manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; Yan H reviewed the research protocol and conducted quality control; and all authors reviewed the manuscript and approved the final submitted version.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the General Hospital of Northern Theater Command, approval No. Y(2026)209.
Informed consent statement: Informed consent was obtained from all subjects involved in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Hao Yan, Associate Chief Physician, Research Fellow, Department of Interventional Vascular Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang 110001, Liaoning Province, China.
Received: March 17, 2026
Revised: April 10, 2026
Accepted: May 18, 2026
Published online: July 27, 2026
Processing time: 132 Days and 1.3 Hours
Revised: April 10, 2026
Accepted: May 18, 2026
Published online: July 27, 2026
Processing time: 132 Days and 1.3 Hours
Core Tip
Core Tip: Transarterial chemoembolization + immunotherapy co-treatment can significantly improve short-term objective response rate and disease control rate in intermediate-advanced hepatocellular carcinoma patients and more effectively regulate relevant serum biomarkers. Radiomic features extracted from pre-treatment imaging can serve as a potential strategy for constructing personalized efficacy prediction models.